New developments in the treatment of primary biliary cholangitis

Česká verze

Authors: L. Husová
Authors place of work: Centrum kardiovaskulární a transplantační chirurgie, Brno
Published in the journal: Gastroent Hepatol 2025; 79(5): 396-401
Category: Přehledová práce
doi: https://doi.org/10.48095/ccgh2025396

Summary

Primary biliary cholangitis is a chronic, immunologically mediated, progressive liver disease characterized by progressive destruction of small bile ducts, resulting in cholestasis, liver fibrosis with the development of liver cirrhosis and all of its complications. These ultimately lead to liver failure, resulting in death or the need for a liver transplant. Early and effective treatment is a key factor in influencing the prognosis. The disease mainly affects women, accounting for 90% of cases. Diagnosis is possible based on an elevation of serum alkaline phosphatase (ALP) above 1.5-times the normal level for 6 months and in combination with the presence of antimitochondrial antibodies (AMA) ≥ 1 : 40 or specific antinuclear antibodies (ANA) sp100, gp210, or a combination of elevated serum ALP with typical histological findings found during liver biopsy. Although ursodeoxycholic acid (UDCA) remains the treatment of choice, unfortunately some patients do not tolerate this treatment or do not respond adequately to it. Second-line treatment is currently available –⁠ peroxisome proliferator-activated receptor (PPAR) agonists, delta (PPAR-d) or dual agonists (PPAR-a/d). Seladelpar (PPAR-d) and elafibranor (PPAR-a/d) are promising treatment alternatives due to their anti -⁠ -inflammatory and antifibrotic properties.

Keywords:

primary biliary cholangitis – alkaline phosphatase – AMA antibodies – ANA antibodies – ursodeoxycholic acid – elafibranor – seladelpar

Zdroje

1. Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology 1959; 37 : 574–586.

2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2): 237–267. doi: 10.1016/ j.jhep. 2009.04.009.

3. Addison T, Gull W. On a certain affection of the skin-vitiligoidea-a plana, B tuberosa. Guys Hosp Rep 1851; 7 : 265–276.

4. Mac MH, Thannhauser SJ. Xanthomatous biliary cirrhosis; a clinical syndrome. Ann Intern Med 1949; 30 (1): 121–179. doi: 10.7326/0003-4819-30-1-121.

5. Ahrens EH, Payne MA, Kunkel HG et al. Primary biliary cirrhosis. Medicine 1950; 29 (4): 299–364. doi: 10.1097/00005792-195012000-00002.

6. Beuers U, Gershwin ME, Gish RG et al. Changing nomenclature for PBC: from „cirrhosis“ to „cholangitis“. J Hepatol 2015; 63 (5): 1285–1287. doi: 10.1016/j.jhep.2015.06.031.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67 (1): 145–172. doi: 10.1016/j.j hep.2017.03.022.

8. Gershwin ME, Selmi C, Worman HJ et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42 (5): 1194–1202. doi: 10.1002/hep.20907.

9. Jones DE, Bhala N, Burt J et al. Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55 (4): 536–541. doi: 10.1136/gut.2005. 080317.

10. Prince M, Chetwynd A, Newman W et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123 (4): 1044–1051. doi: 10.1053/gast.2002.36027.

11. Phillips JR, Angulo P, Petterson T et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96 (9): 2745–2750. doi: 10.1111/j.1572-0241. 2001.04134.x.

12. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atheroscierotic risk: a systematic review. Atherosclerosis 2007; 194 (2): 293–299. doi: 10.1016/ j.atherosclerosis.2006.11.036.

13. Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147 (6): 1338.e5–1349.e5. doi: 10.1053/ j.gastro. 2014.08.029.

14. Shi J, Wu C, Lin Y et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101 (7): 1529–1538. doi: 10.1111/j.1572-0241. 2006.00634.x.

15. Corpechot C, Carrat F, Bonnand AM et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32 (6): 1196–1199. doi: 10.1053/jhep.2000.20240.

16. Lammers WJ, Hirschfield GM, Corpechot C et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149 (7): 1804.e4–1812.e4. doi: 10.1053/ j.gastro. 2015.07.061.

17. Murillo Perez CF, Harms MH, Lindor KD et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020; 115 (7): 1066–1074. doi: 10.14309/ ajg.0000000000000557.

18. Kumagi T, Guindi M, Fischer SE et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (10): 2186–2194. doi: 10.1038/ ajg.2010.216.

19. Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (7): 631–643. doi: 10.1056/NEJMoa1509840.

20. Corpechot C, Lemoinne S, Soret PA et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology 2024; 79 (1): 39–48. doi: 10.1097/ HEP.0000000000000529.

21. Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun 2023; 6 : 100188. doi: 10.1016/j.jtauto.2023.100188.

22. SPC Iqirvo 2025. Souhrn údajů o přípravku. 2025 [online]. Dostupné z: chrome-extension: // efaidnbmnnnibpcajpcglclefindmkaj/https: //ec.europa.eu/health/documents/community-register/2024/20240919163733/anx_163733_ cs.pdf.

23. Kowdley KV, Bowlus CL, Levy C et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024; 390 (9): 795–805. doi: 10.1056/ NEJMoa2306185.

24. SPC Lyvdelzi. Souhrn údajů o přípravku. 2025 [online]. Dostupné z: chrome-extension: //efaidnbmnnnibpcajpcglclefindmkaj/ https: //www.ema.europa.eu/cs/documents/ product-information/lyvdelzi-epar-product-information_cs.pdf.

25. Hierschfield GM, Bowlus CL, Mayo MJ et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024; 390 (9): 783–794. doi: 10.1056/NEJMoa2312100.

26. Ashraf T, Abunada O, Seerani N et al. The role of seladelpar in primary biliary cholangitis: a systematic review and meta-analysis. BMC Gastroenterology 2025; 25 : 224. doi: 10.1186/s12 876-025-03812-3.

ORCID autorky

L. Husová 0000-0002-9639-2541.

Doručeno/Submitted: 27. 8. 2025

Přijato/Accepted: 11. 9. 2025

MUDr. Libuše Husová, Ph.D.

Centrum kardiovaskulární a transplantační chirurgie

Pekařská 53

602 00 Brno

libuse.husova@cktch.cz